Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Stunt”!...if not following a legit PR release. Remember they have deep pockets for PR. Hope you got something good!
So guess is a bought-deal financing. Partner with glaucoma drug. Hopeful guess:) waiting for for their findings!
According to their website INM-085 is due for its’ final formulation this year. Trials early 2018. This one is also slated for a partnership opportunity, probably due to the costs involved taking it to trials. I believe there was something in the financials saying there maybe some updates or a publishing on INM-085 before year end.
Until they finish the financing I hope. The shorting has been high the last few months... so that usually indicates the company shorting their shares. Hopefully almost done. This is a long... let them “do what they do”.
http://thecse.com/en/listings/life-sciences/inmed-pharmaceuticals-inc
Try this link for financials on CSE listed companies
Sorry Antonchirurh for the tardy response. I see the numbers and appreciate... but the platforms look like apples vs oranges to me, and my fault for not elaborating in my first response. I do appreciate the comparisons...but quite biased in opinion as I’ve been following this stock “too long”;)
Not even close...
Cannabosides – A New Class of Cannabinoid Pharmaceuticals
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.
Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease (“IBD”) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or abdominal pain. Approximately 1.4 million Americans have IBD, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are typically designed to overcome well-known drawbacks of currently available therapies. Vitality’s prodrug technology enables the selective targeting of specific tissues or organs, including the gut or brain, enabling the drug to have a more targeted effect. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
Ask Revive Therapeutics Rvv. They already have a deal with Inmed. Maybe GW does too... but only time will tell. I’m staying long with this stock. They’re “all in” with Biosynthesis... and probably for good reason. Imagine this stock with a secure revenue stream and the pipeline they’ve introduced. Gotta be worth something you’d think ;)
The potential “cure” of EB is huge and something they mentioned in the Forbes article. You have got to be stupid or brilliant to put it all out there. The spinoffs on just EB alone are enough to keep me interested. I think the team assembled are prepared to stand behind their word and see this stock through going forward.
As far as worth??? I guess we’ll have to see. But a small guess at the mention of GW in a news release will see us over $5. A guess only!
Anybody have a take on Inmed Frankfurt listing? Noticed it’s been hashtagged on some of the latest press. Seems to be active... but haven’t seen anything from the company on the listing? MWG2
https://www.bloomberg.com/quote/MWG2:GR
Long and strong... Canadian or Not!
Park it.... and forget it for at least 2 years. I've seen this go up and down for a few years now and keep improving my position:)
Thanks once again! I'm parked here for the long term... just happy to see the sell off has finally ended. The price still doesn't make sense seeing the last pp sell... but sure recovery and beyond is just around the corner.
Thanks for taking the time to break that down for us!
What do you make of this new raise for 15 million. I thought they already had enough in the bank account to get them through for awhile?
http://thecse.com/sites/default/files/INMEDPHARM_PreliminaryShortFormPr_20170831.pdf
Revive Therapeutics Appoints Dr. Ram Subramanian, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases
Marketwired via Yahoo Finance CanadaAug 15 07:00 AM
Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the joint venture with InMed Pharmaceuticals Inc. for development ...
Why doesn't Inmed ever talk about this joint venture... yet it's all over the internet?
Good plan!
Guess I've been invested in this stock a little too long... and know the pattern. Wish I'd been trading it... but happy being a long term holder.
Sorry if my read was "off" for you :)
Good luck out there!
A "Luke-warm" news release, followed by the DumpTards crawling out from under their rocks is typical of this company. Notice the company seems to be the biggest buyer while they try and squeeze out the nervous and day traders.
Options exercised @.45 = $517 000.00 on top of 8.5 million already in the bank. So many options at much lower prices are still hanging unexercised @ lower prices. Wonder what the money is for? Hmmm....if the management of the company is paying up willingly I think all us long term holders should feel pretty secure at this point.
Thanks... I made some calls and figured it out myself.
The future looks very nice ;)
Q: Why the rush to exercise the latest options @ .45 (can) issued when so many are still outstanding at such lower prices still unexercised...especially when the stock can be bought in the open market at a lower price? These options issued don't appear to have any warrants attached either.
http://thecse.com/sites/default/files/CNSX_Form_11_-_Notice_of_Proposed_Stock_Option_June_2-2017_FINAL.pdf
I think we'll see Sazzad, Bogart, Schneider and Muhammed all close their options by week end and hopefully this downward turn will be all done. Last call for cheapies IMO
Smart move!
Effective May 31, 2017, the Company entered into a Master Service Agreement and related Research Study Proposal with Atera SAS to perform certain research, development and testing services for InMed.
This must be something regarding EB.
SGH potential acquisition of a license would be something Inmed needs right now. Not too mention the obvious connections. Am I sniffing glue?
Looks like somebody took a position in the financing from the home team:
31 $IN
InMed Pharmaceuticals Inc. (formerly Cannabis Technologies Inc,) Mancini, Alexandra Diane Janet
5 - Senior Officer of Issuer
10 - Acquisition or disposition in the public market +50,000 0.6500 50,000
2017-05-31 2017-05-31 $IN
InMed Pharmaceuticals Inc. (formerly Cannabis Technologies Inc,) Mancini, Alexandra Diane Janet
5 - Senior Officer of Issuer
10 - Acquisition or disposition in the public market +100,000 0.4500 100,000
Now it's halted.
Interesting news out today. Inmed very own SVP Chris Bogart is CEO of SGH the company acquiring Marapharm (MDM.C). Wonder if there is any connection?
Standard Graphite to acquire Marapharm
2017-06-01 08:13 ET - News Release
Mr. Chris Bogart reports
STANDARD SIGNS LOI TO ACQUIRE LATE-STAGE CANNABIS LP APPLICANT MARAPHARM AND UNDERTAKES PRIVATE PLACEMENT
Standard Graphite Corp. has entered into a letter of intent (LOI) to acquire Marapharm Inc., a licensed producer (LP) applicant under Health Canada's access to cannabis for medical purposes regulations (ACMPR).
Private Placement
The Company also announces that it is undertaking a non-brokering private placement to raise $1,000,000 of units at price of $0.15 per unit. Each unit will consist of one common share of the Company and one-half of one common share purchase warrant. Each full warrant will be exercisable into one common share of the Company at $0.25 per share for 18 months. Proceeds are to be used for general corporate purposes and the evaluation of opportunities in the cannabis market, including the proposed acquisition of Marapharm. All securities issued in connection with the private placement will be subject to a 4 month hold period. Closing of the placement is subject to TSX Venture Exchange acceptance.
About Marapharm
Marapharm, which is an advanced stage LP applicant under the ACMPR, began assembling people and the proposed build out and property, located in Kelowna, British Columbia, for its LP application in 2014. The proposed 11 acre parcel in Kelowna, British Columbia was confirmed by the Provincial government to be legally zoned as proper use for medical marijuana production. The property can accommodate a two story, 40,000-square-foot facility, with the requisite parking area and green space. The construction contract is currently being prepared to build a Phase I, 20,000-square-foot production facility with an additional 20,000 square feet of additional space planned for year two. It is anticipated that the production facility will be operational six months following receipt of the building permits. Subject to completion of the acquisition and requisite financing, the Company will cause Marapharm to submit such permit applications after closing of the acquisition.
Acquisition Terms
Pursuant to the terms of the LOI and as consideration for the acquisition of Marapharm, Standard will issue to the sole shareholder of Marapharm, namely Marapharm Ventures Inc., the following: 35,100,000 common shares of Standard (the "Standard Shares") in escrow, subject to release therefrom as follows: 10% on closing and thereafter the balance over 36 months; and
a $2,500,000 convertible note of Standard, such note to be, at Standard's option, either: (i) paid in cash on the twentieth trading day ("Trigger Date") after the public dissemination of a news release announcing the receipt of a cannabis LP under the ACMPR; or (ii) converted into common shares of Standard valued using the 20 day volume-weighted average trading price of Standard shares on the Trigger Date.
The proposed acquisition is subject to customary conditions, including satisfaction with diligence investigations, entering into a definitive agreement, necessary corporate approvals and applicable exchange acceptance. A portion of the proceeds of the private placement is intended to be used in furtherance of the Company's diligence investigations and negotiation of a definitive agreement.
The Cannabis Market
According to a recent report from the consulting firm Deloitte, the Canadian retail cannabis market is projected to be between $4.9 billion and $8.7 billion annually. Deloitte estimates that satisfying the recreational cannabis market will mean producing 600,000 kilograms of marijuana annually - far more than the existing licensed producers under the ACMPR grow for medicinal purposes.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
Not much hurry here. The warrants have 2 years before being exercised...better be here for the long term, although I think there's news coming out of the pipeline soon.
Financing is finally done. Raised 5.75 million total with full exercise of over-allotment.
Totally controlled! Raymond James Canadian side Cannacord U.S. these guys will take this where they want it to go. I'm long term so don't really care about these swings. Could've made a ton if I was trading like some of you...but doesn't make sense to me. This company has way too much on the go! Do your dd!
Feb 22/2017
Revive and InMed will endeavor to enter into a definitive agreement within 30 days of the execution of the term sheet. Pursuant to the signing of a definitive agreement, InMed will grant Revive the exclusive worldwide rights to develop and commercialize the target cannabinoid(s) discovered from InMed’s proprietary in silico drug/disease targeting technology. Under the term sheet, InMed will receive an upfront payment and will be eligible to receive additional milestone payments upon achievement of certain predefined pre-clinical clinical, regulatory and commercial targets, as well as royalties on commercial sales. The term sheet agreement is not binding and remains subject to further negotiation and definitive documentation. Further announcements will be made on the status of this transaction, and the details of the commercial terms.
Yes, he sorta put his foot in his mouth with that statement. But if they can cure this disease Inmed's topical treatment would certainly be a far superior alternative to the stem-cell treatment.
Quote from Forbes article about EB:
Chief Executive Officer Eric Adams said, “It's a very devastating disease and we found out in early testing that this set of cannabinoids treat the major symptoms of this disease giving them a tremendous amount of relief, but it may also reverse the disease, which is something no one has really talked about before.”
Butterfly Boy w/EB in the news. Successful stem-cell transplant. http://www.ottawasun.com/2017/05/17/mom-we-did-it-whats-next-for-ottawas-butterfly-boy-jonathan-pitre
The success of this method has not been great and the method is horrible on the family. Hurry up Inmed and get your trials started. These children and families shouldn't have to go through this a moment longer!
Which pp are you talking of? The one from Jan.17? Details might be a little different from what is being claimed?
Title Date Location Info
Canaccord Genuity's Cannabis Conference May 10, 2017 New York, NY
The Intercontinental Barclay New York
Grand Ballroom & Empire Ballroom
That term sheet with RVV is way overdue
This company has complete control over share price. Just ask Raymond James...I'm thinking a "house account". They drove this run up. Let's see where they decide to take it now. I can't see this pp being an under sale of current price. But I can certainly be wrong.
Here comes the PP!